Treatment Horizons

On November 21, 2017, the U.S. Food and Drug Administration (FDA) approved the first-ever two-drug once-daily single-pill regimen for the maintenance treatment of adults...

At the 16th European AIDS Conference in Milan, Italy, on October 25, 2017, Janssen Pharmaceutica, NV announced the results of its Phase 3 AMBER...

A newly completed study of 358 serodiscordant gay couples has not found a single case of HIV transmission in 16,889 acts of condomless anal...

On July 26, 2017, the Centers for Disease Control and Prevention released new data on the nation’s progress in HIV testing and treatment, showing...

Shock Value Research on SMYD2 shows potential to wake up the HIV reservoir by Chael Needle HIV latency—where HIV hides out in reservoirs, dormant and beyond the...

Chronic inflammation means the immune system is imbalanced—a natural immune response has persisted, or immune regulation is not working properly. Research has shown that...

Last month, the Member States of the United Nations adopted the “Political Declaration on HIV and AIDS: On the Fast-Track to Accelerate the Fight...

Chronic Relief? A self-injectable monoclonal antibody vies to become a monotherapy by Chael Needle Anti-HIV agents currently being researched these days seem split between (1) improving regimens...

More Than Surviving A new report calls for aging well with HIV by Chael Needle More than half of the 1.2 million people living with HIV in...

Undetectable is a worthy goal, no doubt about it. A suppressed viral load very often means the individual living with HIV is adherent to...